Advanced Therapeutic Interventions Targeting Mycobacterium Tuberculosis

Document Type : Review Article

Authors

1 Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad. Bab Al-Mouadam, 10001. Baghdad, Iraq.

2 Assistant professor, Department of Community & Psychiatric Nursing, Faculty of Nursing, King Khalid University, Mahayil, Asir Region, KSA.

3 MD pharmacology, Professor, HOD, MGM Medical College, Vashi, Navi Mumbai.

4 Principal Scientist, ICAR-National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI), Bengaluru, Karnataka, India.

10.32592/ARI.2025.80.1.19

Abstract

Tuberculosis infection (TBI), caused by Mycobacterium tuberculosis (M.tb) antigens, presents with or without clinical signs of active TB disease and is a persistent global threat despite efforts to eradicate it. The emergence of HIV/AIDS has hindered complete eradication. Recent research has focused on vaccines, diagnostics, and treatment. This review examines vulnerable populations, high-risk groups, and socio-economic factors influencing TBI prevalence. It also explores the intersection of TBI and the COVID-19 pandemic, including healthcare disruptions and transmission dynamics. Advances in TBI diagnosis, biomarkers, prophylactic therapies, and combination treatments are discussed, along with the integration of artificial intelligence (AI) in TBI therapy to optimize treatment and personalize care. Vulnerability to TBI varies based on age, socio-economic status, and immune status. High-risk groups include those with compromised immune systems, the elderly, and those in crowded or poorly ventilated settings. Socio-economic factors such as poverty and limited healthcare access also contribute to TBI prevalence. The COVID-19 pandemic has disrupted TBI diagnosis and treatment, with limited healthcare access impacting outcomes. Changes in healthcare delivery, like telemedicine, may have long-term impacts on TBI care. Improved biomarkers, like interferon-gamma release assays (IGRAs), offer faster TBI diagnosis. Prophylactic therapies, such as isoniazid preventive therapy (IPT), reduce active TB risk in high-risk groups. Combination treatments are being evaluated for drug-resistant strains.AI integration in TBI therapy could lead to better outcomes by analyzing patient data for personalized treatment plans. In conclusion, TBI remains a global health threat requiring ongoing research and innovative approaches for diagnosis and treatment. Advances in diagnosis, prophylactic therapies, and combination treatments, along with AI integration, offer hope for improved outcomes and better patient care.

Keywords

Main Subjects

References

  1. Escalante P, Vadiyala MR, Pathakumari B, Marty PK, Van Keulen VP, Hilgart HR, Meserve K, Theel ES, Peikert T, Bailey RC, Laniado-Laborin R. New diagnostics for the spectrum of asymptomatic TB: from infection to subclinical disease. The International Journal of Tuberculosis and Lung Disease. 2023;27(7):499-505.
  2. Sekyere JO, Reta MA, Maningi NE, Fourie PB. Antibiotic resistance of Mycobacterium tuberculosis complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics. Journal of Infection. 2019;79(6):550-71.
  3. Achkar, J.M.; Jenny-Avital, E.R. Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response. J. Infect. Dis. 2011;204:S1179–S1186.
  4. Peterson AB, Zhou H, Thomas KE. Disparities in traumatic brain injury-related deaths—United States, 2020. Journal of safety research. 2022;83:419-26.
  5. MacNeil A, Glaziou P, Sismanidis C, Date A, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward meeting global targets—worldwide, 2018. Morbidity and Mortality Weekly Report. 2020;69(11):281.
  6. Steingart KR, Ramsay A, Pai M. Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis. Expert review of anti-infective therapy. 2007;5(3):327-31.
  7. Yildiz I. Applications of magnetic nanoparticles in biomedical separation and purification. Nanotechnology Reviews. 2016;5(3):331-40.
  8. Zhang Y, Ren F, Wang G, Liao T, Hao Y, Zhang H. Rapid and sensitive pathogen detection platform based on a lanthanide-labeled immunochromatographic strip test combined with immunomagnetic separation. Sensors and Actuators B: Chemical. 2021;329:129273.
  9. Getahun, H.; Matteelli, A. Chaisson, R.E.; Raviglione, M. Latent Mycobacterium Tuberculosis Infection. N. Engl. J. Med. 2015;372:2127–2135.
  10. Getahun, H.; Matteelli, A.; Abubakar, I.; Aziz, M.A.; Baddeley, A.; Barreira, D.; Den Boon, S.; Borroto Gutierrez, S.M.; Bruchfeld, J.; Burhan, E.; et al. Management of Latent Mycobacterium Tuberculosis Infection: WHO Guidelines for Low Tuberculosis Burden Countries. Eur. Respir. J. 2015;46:1563–1576.
  11. World Health Organization Global Tuberculosis Report 2021. Available online: 2021 (accessed on 9 February 2022).
  12. Ruhwald, M.; Carmona, S.; Pai, M. Learning from COVID-19 to Reimagine Tuberculosis Diagnosis. Lancet Microbe 2021, 2, e169–e170. Tuberculosis: An Analysis of Notification Data. Lancet Glob. Health 2022;10:e1774–e1781.
  13. Zimmer, A.J.; Klinton, J.S.; Oga-Omenka, C.; Heitkamp, P.; Nawina Nyirenda, C.; Furin, J.; Pai, M. Tuberculosis in Times of COVID-19. J. Epidemiol. Community Health 2022;76:310–316.
  14. Haas, M.K.; Belknap, R.W. Diagnostic Tests for Latent Tuberculosis Infection. Clin. Chest Med. 2019;40:829-837.
  15. Reis C, Wang Y, Akyol O, Ho WM, Applegate II R, Stier G, Martin R, Zhang JH. What’s new in traumatic brain injury: update on tracking, monitoring and treatment. International journal of molecular sciences. 2015;16(6):11903-65.
  16. Sotgiu, G.; Saderi, L.; Petruccioli, E.; Aliberti, S.; Piana, A.; Petrone, L.; Goletti, D. QuantiFERON TB Gold Plus for the Diagnosis of Tuberculosis: A Systematic Review and Meta-Analysis. J. Infect. 2019;79: 444–453.
  17. World Health Organization. WHO Operational Handbook on Tuberculosis: Module 2: Screening: Systematic Screening for Tuberculosis Disease; World Health Organization: Geneva, Switzerland, 2021. ISBN 978-92-4-002261-4.
  18. Wang XW, Pappoe F, Huang Y et al .Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in children: a meta-analysis. Clin Lab. 2015;61:1775–1785.
  19. Basu S, Hess S, Braad PE, Olsen BB, Inglev S, Høilund-Carlsen PF. The basic principles of FDG-PET/CT imaging. PET clinics. 2014;9(4):355-70.
  20. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M,Abe S. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000;161: 1786–89.
  21. Ghodmare R, Narang R, Narang P. Evaluation of nitrate reductase assay on Lowenstein–Jensen medium for drug susceptibility testing of Mycobacterium tuberculosis. Journal of Mahatma Gandhi Institute of Medical Sciences. 2019;24(2):78-81.
  22. Golia S, Hittinahalli V, Nirmala AR, Sangeetha KT, Asha SK. A comparative study of auramine staining using led fluorescent microscopy with Ziehl-Neelsen staining in the diagnosis of pulmonary tuberculosis. Journal of Evolution of Medical and Dental Sciences. 2013;2(20):3450-7.
  23. Zhu L. Construction of Lux-based promoter-reporter platforms in mycobacterium bovis BCG for screening new anti-TB drugs.
  24. Froeschle, J.E., Ruben, F.L., Bloh, A.M., Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin. Infect. Dis. 34, E12-13. 2002.
  25. Llibre A, Bondet V, Rodero MP, Hunt D, Crow YJ, Duffy D. Development and validation of an ultrasensitive single molecule array digital enzyme-linked immunosorbent assay for human interferon-α. JoVE (Journal of Visualized Experiments). 2018;14(136):e57421.
  26. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, Butcher PD. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC medicine. 2016;14(1):1-7.
  27. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS medicine. 2011;8(7):e1001061.
  28. Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MP, Schmitt P, Wai J. Breath biomarkers of active pulmonary tuberculosis. Tuberculosis. 2010;90(2):145-51.
  29. Petersen, E.; Chakaya, J.; Jawad, F.M.; Ippolito, G.; Zumla, A. Latent Tuberculosis Infection: Diagnostic Tests and When to Treat. Lancet Infect. Dis. 2019;19:231–233.
  30. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D, Sivaruban T, Ngo C. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. medRxiv. 2020.
  31. Mukundan H, Kumar S, Price DN, et al. Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor. Tuberculosis (Edinb) 2012;92:407–16.
  32. Alsdurf, H.; Hill, P.C.; Matteelli, A.; Getahun, H.; Menzies, D. The Cascade of Care in Diagnosis and Treatment of Latent. Tuberculosis Infection: A Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2016;16:1269–1278.
  33. Mezochow A, Thakur K, Vinnard C. Tuberculous meningitis in children and adults: new insights for an ancient foe. Current neurology and neuroscience reports. 2017;17:1-2.
  34. Kerantzas CA, Jacobs WR. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio. 2017;8(2):e01586–16.
  35. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert opinion on pharmacotherapy. 2014;15(10):1351-70.
  36. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863.
  37. Yegian D. Biology of tubercle bacilli in necrotic lesions. Am Rev Tuberc. 1952;66(5):629–631.
  38. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–S279.
  39. McGrath M, Gey van Pittius NC, van Helden PD, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):292–302.
  40. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(4):1522–1524.
  41. WHO consolidated guidelines on tuberculosis: Module 2: screening – systematic screening for tuberculosis disease. (2021) Geneva: World Health Organization. 2022.
  42. Garrido JB, Alías Hernández I, Bonillo Perales A, Rubí Ruiz T, González Jiménez Y, González‐Ripoll Garzón M, Moriana Maldonado J, González de Rojas JD, Martínez Lirola M, Fornovi Vives JJ. Usefulness of thoracic CT to diagnose tuberculosis disease in patients younger than 4 years of age. Pediatric pulmonology. 2012;47(9):895-902.
  43. Swingler GH, du Toit G, Andronikou S et al. Diagnostic accuracy of chest radiography in detecting mediastinal lymphadenopathy in suspected pulmonary tuberculosis. Arch Dis Child. 2005;90:1153–1156.
  44. Khan FA, Pande T, Tessema B, Song R, Benedetti A, Pai M, Lönnroth K, Denkinger CM. Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. European Respiratory Journal. 2017;50(1).
  45. Reddy, M.M.; Thekkur, P.; Ramya, N.; Kamath, P.B.T.; Shastri, S.G.; Kumar, R.B.N.; Chinnakali, P.; Nirgude, A.S.; Rangaraju, C.; Somashekar, N.; et al. To Start or to Complete? —Challenges in Implementing Tuberculosis Preventive Therapy among People Living with HIV: A Mixed-Methods Study from Karnataka, India. Glob. Health Action. 2020;13:1704540.
  46. Jha AM, Veerakumar R, Puhazhendhi T, Kesavan R, Naveenraj NS. Immunotherapy’s promising potential for cancer treatment: oncology-immunotherapy for cancer. Int J Trends Oncoscience. 2023:25-35.
  47. Ahmad SR, Velhal GD. Study of treatment outcome of new sputum smear positive TB cases under DOTS-strategy. Int J Pharm Biol Sci. 2013;4(3):1215-22.
  48. Talluri Rameshwari KR, Jayashree K, Anuradha K. Raghuraj Singh Chouhan and Sumana K, an overview of extra pulmonary tuberculosis in smear negative cases and their analysis. Int J Life Sci Pharm Res. 2021;11(1):204-17.
  49. Nikbakht, G. Novel Insights into Infection and immunity. Iranian Journal of Veterinary Medicine, 2022; 16(2): 99-100.
  50. Rasooli, A., Nouri, M., Seyfi Abad Shapouri, M. R., Mohseni-Parsa, S., Baghbanian, H. R., Lotfi, M., Daghari, M. Serological Detection of SRMV, BVDV, BHV-1and BEFV in Camels (Camelus dromedarius) in Southwest Iran. Iranian Journal of Veterinary Medicine, 2023;17(2):139-148.
Archives of Razi Institute
Volume 80, Issue 1
January and February 2025
Pages 19-35

Files

Share

How to cite

Statistics